Genmab retained by Merrill at buy

Genmab AS was retained by Merrill Lynch analyst Peter Welford at a buy rating with a price target on the stock of DKK 150 per share following a licensing agreement with Serono SA for its lymphoma drug HuMax-CD4. In Copenhagen, Genmab shares Monday were down DKK 1.50, or 1.33%, at DKK 111 on volume of 72,924 shares versus the three-month running average of 95,088.3 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.